Global Coalition for Adaptive Research Inc
Public records show a registered, tax-exempt organization in good standing.
What it says it does
OUR MISSION IS PIONEERING COLLABORATIVE, INNOVATIVE CLINICAL TRIALS TO SPEED THE DISCOVERY AND DEVELOPMENT OF CURES.
- Income
- $32.4 million
- Spending
- $32.6 million
- Spent on programs
- 92%
- Reserves
- 16.3 months of spending
- Largest source of income
- fees for its services, 91%
- Employees
- 40
- Volunteers
- 5
- Highest pay
- $1.3 million, chief executive officer/president
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Good: 83 out of 100. Higher than 60% of charities in its peer group (medical research, $10m to $100m).
Reserves
35 of 35Spendable reserves would cover 16.3 months of spending.
Debt
10 of 20It owes 43% of what it owns.
Living within its means
8 of 15Spending exceeded income by 1% of income.
Income trend
15 of 15Income rose 17% on the year before.
Spending floor
15 of 1592% of spending went to programs and raising each dollar of donations cost 0 cents.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 100 out of 100. Higher than 45% of charities in its peer group (medical research, $10m to $100m).
Independent board
25 of 255 of 8 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
5 of 5Sets its chief executive's pay through independent review and comparison.
Independent check of accounts
15 of 15Its accounts were audited by an independent accountant.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (2)
- $27.4 million spent. GBM AGILE (GLIOBLASTOMA ADAPTIVE GLOBAL INNOVATIVE LEARNING ENVIRONMENT) IS UNIQUELY DESIGNED AS A LONG-STANDING PLATFORM WITH THE ABILITY TO TEST MULTIPLE THERAPIES AT THE SAME TIME AGAINST A COMMON CONTROL (OR STANDARD OF CARE). THE PURPOSE IS TO EVALUATE MULTIPLE INVESTIGATIONAL TREATMENTS FOR EITHER NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA TO DETERMINE IF ANY OF THESE STUDY TREATMENT(S) IMPROVE OVERALL SURVIVAL AS COMPARED TO STANDARD TREATMENTS.
- $2.5 million spent. OTHER ONGOING PROGRAMS OR PROGRAMS IN DEVELOPMENT GCAR SERVES AS THE REGULATORY SPONSORSHIP OF THE MILITARY AND VETERANS PTSD ADAPTIVE PLATFORM CLINICAL TRIAL (M-PACT). PARTNERING WITH OPERATIONAL MEDICAL SYSTEMS, PART OF THE DEFENSE HEALTH AGENCY, GCAR IS CONDUCTING AN ADAPTIVE PLATFORM TRIAL AT IS EVALUATING MULTIPLE PHARMACOTHERAPEUTIC INTERVENTIONS FOR THE TREATMENT OF PTSD FOR ACTIVE-DUTY SERVICE MEMBERS AND VETERANS WITH PTSD AT MULTIPLE CLINICAL SITES IN THE US. THIS PROGRAM IS SUPPORTED BY A PROJECT TEAM THAT ALSO INCLUDES REPRESENTATIVES FROM THE U.S. AIR FORCE, ARMY, NAVY, AND SPECIAL OPERATIONS COMMAND. GCAR IS COMMITTED TO DESIGNING, LAUNCHING, AND OVERSEEING SEVERAL INITIATIVES CURRENTLY IN DEVELOPMENT TO RAPIDLY AND EFFICIENTLY EVALUATE NEW TREATMENTS FOR RARE AND LETHAL DISEASES, INCLUDING PANCREATIC CANCER, BILIARY TRACT CANCER, HIGH AND LOW GRADE SEROUS OVARIAN CANCER, AND NEUROFIBROMATOSIS. GCAR ALSO SUPPORTS EDUCATION, OUTREACH, AND CLINICAL COMMUNITY ENGAGEMENT TO ADDRESS THESE URGENT UNMET NEEDS.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated November 6, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2025.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since April 2018.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated November 4, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.